dr reddy's glp-1 drugs portfolio 2025 Say What?! A Magic Medication for Weight Loss? Dr Reddys eyes global GLP-1

This state-of-the-art narrative review synthesizes current evidence from clinical trials, pharmacovigilance databases, and real-world cohorts to provide a comprehensive evaluation of the safety and tolerability of GLP-1RAs and tirzepatide

Our results are generally consistent in direction and magnitude with the existing clinical research, including trials showing reduced heavy alcohol consumption among those with obesity,14 reduced drinking in an experimental bar setting,12 and pharmacoepidemiological analyses showing that GLP-1 receptor agonists are associated with lower incidence and recurrence of alcohol use disorder,2 reduced need for tobacco use related care,5 lower incidence and relapse of cannabis use disorder,4 and reduced risk of opioid overdose in patients with opioid use disorders.8 Our results show that among people with a pre-existing SUD, GLP-1 receptor agonist use was associated with a reduced risk of several adverse clinical outcomes (SUD related emergency department visits, hospital admission, and mortality, drug overdose, and suicidal attempt or ideation)

Body-mass index and mortality among 1.46 million white adults

1 Orforglipron availabililty Orforglipron clinical trials As of early 2024, Orforglipron is in Phase 3 clinical trials for both obesity and type 2 diabetes 2

In HFpEF, the effects of the drugs on cardiac function and structure have not yet been investigated

Bariatric Surgery and Long-Term Durability of Weight Loss